Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,263 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,110 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,003)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01479608 | Liver Transplantation and Colorectal Cancer | recruiting | N/A | 25 | Oslo University HospitalOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05678270 | A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 70 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05794048 |
| METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors(PROMETHEP) |
| recruiting |
| N/A |
| 300 |
| Assistance Publique - Hôpitaux de ParisOTHER |
| 1 |
| Feb 7, 2024 |
| clinicaltrials |
| NCT06236568 | Impact of Graft Reconditioning With Hypothermic Machine Perfusion on HCC Recurrence After Liver Transplantation | recruiting | N/A | 40 | Azienda Ospedaliero-Universitaria di ModenaOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06245330 | A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Ascentawits Pharmaceuticals, LtdINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT02215889 | Partial Liver Segment 2/3 Transplantation Study | recruiting | Phase 1 / Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT03494946 | Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer(SECAIII) | recruiting | N/A | 30 | Oslo University HospitalOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06244225 | HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 38 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06242067 | Second-line Treatment of Metastatic Colorectal Cancer(BEV-TASIRI) | recruiting | Phase 2 | 50 | Qilu Hospital of Shandong UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05952947 | HRYZ-T101 Injection for HPV18 Positive Solid Tumor | recruiting | Phase 1 | 32 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06220617 | Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC) | recruiting | — | 3,600 | Zhejiang UniversityOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06229041 | Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi) | recruiting | Phase 3 | 472 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT06229340 | Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations(NТО-RAS) | recruiting | Phase 2 | 20 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | Jan 29, 2024 | clinicaltrials |
| NCT05746897 | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 38 | Hefei TG ImmunoPharma Co., Ltd.OTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT05918094 | Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma | recruiting | Phase 3 | 540 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06098547 | LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma (LIRICA)(LIRICA) | recruiting | N/A | 10 | Azienda Sanitaria OspedalieraOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06222255 | The Safety and Efficacy of Transanal Irrigation in Patients With Sleep Disturbance From Low Anterior Resection Syndrome After Rectal Cancer Surgery (TraLARS)(TraLARS) | recruiting | N/A | 52 | Seoul National University HospitalOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04936581 | Patient Reported Outcomes Following Cancer of the Rectum(PROCaRe) | recruiting | — | 200 | University Hospital Gregorio MarañónOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05967910 | The Effect of Chronic Stress on Efficacy of ICIs in Esophageal Cancer Patients (STRESS-ESCA Study)(STRESS-ESCA) | recruiting | — | 200 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06218810 | Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer | recruiting | Phase 2 | 53 | Fudan UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06219096 | Application of ICG@HSA Complexes in Fluorescence Image-Guided Laparoscopic Anatomical Liver Resection | recruiting | N/A | 100 | West China HospitalOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06205472 | Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC. | recruiting | Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06190665 | DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC | recruiting | N/A | 188 | Zhongda HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT06204484 | MRD-guided Deferred Adjuvant Therapy in Resectable Early-stage Colon Cancer(MIRROR) | recruiting | N/A | 349 | Sun Yat-sen UniversityOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT06201065 | FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial | recruiting | Phase 3 | 200 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2024 | clinicaltrials |
| NCT05245474 | Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer | recruiting | Phase 2 | 186 | Beijing Friendship HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT04235114 | Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET) | recruiting | Phase 1 / Phase 2 | 14 | University of SaskatchewanOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT05140746 | Prediction of Neoadjuvant Chemotherapy Efficacy in Locally Advanced Gastric Cancer | recruiting | N/A | 40 | Ruijin HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06194708 | Reasons for Non-reversal of Temporary Stomas After Surgeries of Mid-low Rectal Cancer （NORESTO Study） | recruiting | — | 235 | Peking Union Medical College HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT06190639 | A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC | recruiting | Phase 2 | 31 | Zhejiang Cancer HospitalOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05833594 | Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma | recruiting | — | 70 | Anhui Provincial HospitalOTHER_GOV | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06061146 | Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC(TCRTOE) | recruiting | Phase 2 | 136 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT04894370 | Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma(SPARTANA) | recruiting | Phase 2 | 34 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT05991102 | Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer(Live-RF) | recruiting | N/A | 12 | Charite University, Berlin, GermanyOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT06168786 | Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC | recruiting | Phase 2 | 40 | Huazhong University of Science and TechnologyOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT05427383 | KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy | recruiting | Phase 2 / Phase 3 | 286 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Dec 19, 2023 | clinicaltrials |
| NCT06173986 | Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer | recruiting | Phase 1 / Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT06155383 | Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | recruiting | Phase 2 | 90 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 14, 2023 | clinicaltrials |
| NCT03908684 | Ultrasound Spectroscopy as Early Indicators of Radiation Treatment Response in Prostate, Rectum and Head & Neck Cancers | recruiting | — | 320 | Sunnybrook Health Sciences CentreOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT06159478 | Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)(Perfume) | recruiting | Phase 2 | 32 | National Cancer Center, JapanOTHER_GOV | 1 | Dec 13, 2023 | clinicaltrials |
| NCT04792892 | ANCA II - Quality of Life and Functional Outcome in Patients With Anal Cancer(ANCAII) | recruiting | — | 600 | Sahlgrenska University HospitalOTHER | 1 | Dec 8, 2023 | clinicaltrials |
| NCT06160596 | Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis(ROSALIND) | recruiting | — | 1,020 | Cure 51OTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT02649647 | Proximally Extended Resection for Rectal Cancer After Neoadjuvant Chemoradiotherapy(PERN) | recruiting | N/A | 240 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT05561504 | Helicobacter Pylori Local Prevalence and Antibiotic Resistance(HelicoPTER) | recruiting | — | 20,000 | Technical University of MunichOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT06017284 | Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer(PTCA199-5) | recruiting | Phase 3 | 100 | Fudan UniversityOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT04745403 | Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)(SAFE-T-HBV) | recruiting | Phase 1 | 10 | Lion TCR Pte. Ltd.INDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04754672 | Aerobic Fitness or Muscle Mass Training to Improve Colorectal Cancer Outcome(AMICO) | recruiting | N/A | 228 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06134388 | Sulfasalazine in Patients With Metastatic Colorectal Cancer | recruiting | Phase 3 | 50 | Tanta UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06136949 | The Theranostic Value of STARD3 in Colorectal Cancer: The STAR Study(STAR) | recruiting | — | 150 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Nov 18, 2023 | clinicaltrials |
Data updated 24 days agoSource updated Feb 7, 2024source: clinicaltrials